Osmosis Films is an award-winning creative studio founded in 2010 which combines global production resources and a unique collaborative process to bring powerful narratives to life across all media types and platforms. Films include the Academy Award short-listed documentary The Lottery and ESPN's 30-for-30 Fernando Nation. Osmosis has created premium documentary content for HBO, ESPN 30 for 30, A&E, A24, Vice and more. For more information, visit www.osmosisfilms.com.
About Abramorama
Abramorama is the preeminent global media distribution and marketing company for nonfiction and music films. An innovator in the focused, personalized form of film distribution, marketing, promotion, and live and event cinema, Abramorama provides customized services to filmmakers, networks, digital services, and IP owners, across all platforms and in all territories. In its over 20 years of operation, Abramorama has been the trusted film partner to many of the most respected global brands in entertainment, including The Beatles, Dolly Parton, Metallica, Pearl Jam, Stevie Nicks, Neil Young, Laurie Anderson, Jimi Hendrix, Green Day, National Geographic, Discovery, AARP, MSNBC, Apple, Amazon, Netflix, HBO, Showtime, Hulu, Universal Music Group, Atlantic Records, Warner Music Group, Sony, Concord Music Group, and many others. Through a powerful global network of cinemas, digital media outlets, and affinity marketing partners, Abramorama strategically implements a unified distribution and audience activation plan for each title. Abramorama is expert at maximizing reach, engagement, marketing spends, and the ROI for content created for target audiences. For more information, visit abramorama.com.
References
- United States Census Bureau. The U.S. Adult and Under-Age-18 Populations: 2020 Census. 2021 Aug 12.
- Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med JCSM. 2017;13(2):307–49.Uhlig B, et al. Sleep Med. 2014;15(6):708-715.
- Roth T. Insomnia: Definition, prevalence, etiology, and consequences. J. Clin. Sleep Med. 2007;15((Suppl. S5)):S7–S10. doi: 10.5664/jcsm.26929.
- Olfson M, Wall M, Liu SM, Morin CM, Blanco C. Insomnia and Impaired Quality of Life in the United States. J Clin Psychiatry. 2018 Sep 11;79(5):17m12020. doi: 10.4088/JCP.17m12020.
- Doghramji K. The epidemiology and diagnosis of insomnia. Am J Manag Care. 2006 May;12(8 Suppl): S214-20. PMID: 16686591.
- de Almondes KM, Costa MV, Malloy-Diniz LF, Diniz BS. Insomnia and risk of dementia in older adults: Systematic review and meta-analysis. J Psychiatr Res. 2016 Jun;77:109-15. doi: 10.1016/j.jpsychires.2016.02.021. Epub 2016 Mar 8. PMID: 27017287.
About Idorsia U.S.
Idorsia U.S., an affiliate of Idorsia, is reaching out for more – we have more ideas, we see more opportunities, and we want to help more patients. To achieve this, we will help develop Idorsia into a leading biopharmaceutical company, with a strong scientific core. With commercial operations based outside of Philadelphia, PA, one of densest communities of life sciences talent in the world, we are helping to realize the company's ambition of bringing innovative medicines from bench to bedside. Our goal is to build a commercial footprint that will deliver Idorsia's deep pipeline of products from its R&D engine to the U.S. market – with the potential to change the lives of many patients. Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017.
For further information, please contact
U.S. Media:
Christopher Clark
Head, U.S. Communications
Idorsia Pharmaceuticals U.S. Inc., One Radnor Corporate Center, Suite 101, 100 Matsonford Rd, Radnor, PA 19087
215-421-4887
Email Contact
www.idorsia.com
Global Investors:
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
Email Contact
www.idorsia.com
The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
View original content to download multimedia:
https://www.prnewswire.com/news-releases/world-premiere-the-quest-for-sleep-a-film-narrated-by-octavia-spencer-explores-peoples-struggles-with-insomnia-and-the-fascinating-science-behind-how-and-why-we-sleep-301503506.html
SOURCE Idorsia Pharmaceuticals U.S.
| Contact: |
| Company Name: Idorsia Pharmaceuticals U.S.
Financial data for Idorsia Pharmaceuticals U.S. |
